

Elizabeth C Okafor

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7896874/elizabeth-c-okafor-publications-by-citations.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

13
papers

1,466
citations

10
h-index

14
g-index

14
ext. papers

1,856
ext. citations

8.7
avg, IF

4.41
L-index

#	Paper	IF	Citations
13	A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. <i>New England Journal of Medicine</i> , 2020 , 383, 517-525	59.2	803
12	Hydroxychloroquine in Nonhospitalized Adults With Early COVID-19 : A Randomized Trial. <i>Annals of Internal Medicine</i> , 2020 , 173, 623-631	8	298
11	Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19). <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa130	1	122
10	Feasibility of SARS-CoV-2 Antibody Testing in Remote Outpatient Trials. <i>Open Forum Infectious Diseases</i> ,	1	78
9	Hydroxychloroquine as Pre-exposure Prophylaxis for Coronavirus Disease 2019 (COVID-19) in Healthcare Workers: A Randomized Trial. <i>Clinical Infectious Diseases</i> , 2021 , 72, e835-e843	11.6	59
8	Safety of Hydroxychloroquine Among Outpatient Clinical Trial Participants for COVID-19. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa500	1	26
7	Symptoms of COVID-19 Outpatients in the United States. <i>Open Forum Infectious Diseases</i> , 2020 , 7, ofaa271		21
6	Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a randomized trial 2020 ,		17
5	Post-exposure prophylaxis or pre-emptive therapy for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): study protocol for a pragmatic randomized-controlled trial. <i>Canadian Journal of Anaesthesia</i> , 2020 , 67, 1201-1211	3	15
4	The bacterial type III-secreted protein AvrRps4 is a bipartite effector. <i>PLoS Pathogens</i> , 2018 , 14, e1006984	9.46	14
3	Safety of Hydroxychloroquine among Outpatient Clinical Trial Participants for COVID-19 2020 ,		8
2	Lessons Learned From Conducting Internet-Based Randomized Clinical Trials During a Global Pandemic. <i>Open Forum Infectious Diseases</i> , 2021 , 8, ofaa602	1	3
1	Correlation between Blood and CSF Compartment Cytokines and Chemokines in Subjects with Cryptococcal Meningitis. <i>Mediators of Inflammation</i> , 2020 , 2020, 8818044	4.3	2